Valuation: CorMedix Inc.

Capitalization 589M 502M 461M 436M 808M 56.39B 816M 5.49B 2.14B 26.74B 2.21B 2.16B 92.93B P/E ratio 2026 *
14.7x
P/E ratio 2027 * 35.5x
Enterprise value 589M 502M 461M 436M 808M 56.39B 816M 5.49B 2.14B 26.74B 2.21B 2.16B 92.93B EV / Sales 2026 *
1.91x
EV / Sales 2027 * 2.09x
Free-Float
99.03%
Yield 2026 *
-
Yield 2027 * -
1 day-1.96%
1 week-2.85%
Current month-1.05%
1 month+3.73%
3 months+2.04%
6 months-34.24%
Current year-35.43%
1 week 7.43
Extreme 7.43
8.15
1 month 7.05
Extreme 7.05
8.15
Current year 6.12
Extreme 6.125
12.29
1 year 6.12
Extreme 6.125
17.43
3 years 2.57
Extreme 2.57
17.43
5 years 2.57
Extreme 2.57
17.43
10 years 0.86
Extreme 0.8605
18.8
Manager TitleAgeSince
Chief Executive Officer 50 2022-05-09
Director of Finance/CFO 54 2025-08-28
Chief Tech/Sci/R&D Officer - 2021-12-31
Director TitleAgeSince
Director/Board Member 67 2015-08-05
Chairman 81 2017-08-02
Director/Board Member 70 2011-08-15
Change 5d. change 1-year change 3-years change Capi.($)
-1.96%-2.85%-36.68%+44.98% 601M
+0.09%+2.22%-9.71%-31.27% 57.84B
+0.64%-1.96%+5.79%-13.25% 7.95B
+6.81%+7.68%+6.53%+115.07% 7.87B
+4.06%+3.32%+15.93%+42.70% 5.26B
+0.35%-6.19%-19.14%+56.67% 4.28B
-0.81%+1.85%+7.00%-18.87% 3.3B
+2.35%+2.72%+57.17%+48.05% 2.87B
-3.19%-2.56%+20.61%+11.89% 2.54B
-0.54%-0.29%+81.04%+38.62% 2.05B
Average +0.78%+0.42%+12.86%+29.46% 9.45B
Weighted average by Cap. +0.85%+1.96%-0.84%-3.49%

Financials

2026 *2027 *
Net sales 308M 263M 241M 228M 423M 29.5B 427M 2.87B 1.12B 13.99B 1.16B 1.13B 48.62B 282M 241M 221M 209M 388M 27.03B 391M 2.63B 1.02B 12.82B 1.06B 1.04B 44.55B
Net income 52.34M 44.64M 40.94M 38.76M 71.82M 5.01B 72.51M 488M 190M 2.38B 196M 192M 8.26B 30.35M 25.89M 23.74M 22.47M 41.65M 2.9B 42.04M 283M 110M 1.38B 114M 111M 4.79B
Net Debt - -
Logo CorMedix Inc.
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.
Employees
191
Date Price Change Volume
26-05-12 7.510 $ -1.96% 1,190,624
26-05-11 7.660 $ -3.28% 1,112,420
26-05-08 7.920 $ 0.00% 858,922
26-05-07 7.920 $ -1.61% 893,174
26-05-06 8.050 $ +4.14% 1,164,884
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
7.510USD
Average target price
15.00USD
Spread / Average Target
+99.73%

Quarterly revenue - Rate of surprise